Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1993-5-25
|
| pubmed:abstractText |
Proresid, mainly consisting of podophyllotoxin derivatives and two glycosides thereof, has been used as a disease-modifying antirheumatic drug in Sweden since the late 1960s. A life-table analysis of Proresid treatment averaging 41 months (range 4-144) in 79 rheumatoid arthritis patients showed a termination rate of 40, 56, 75 and 85% after 1/2, 1, 2 and 4 years, respectively. Dominant reasons for discontinuing therapy were inefficacy (37%) and gastrointestinal symptoms (35%). The risk of discontinuation of therapy due to inefficacy was constant over time, while the risk due to other causes, including side effects, gradually decreased. A comparison with injectable gold therapy showed, after adjusting for confounding factors, that the total termination incidence was higher (p < 0.05) in the Proresid-treated patients. A comparison with the regional cancer register of 334 patients exposed to Proresid for a mean time of 2.2 years showed no increased cancer risk after a mean observation time of 6.1 years.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0300-9742
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
22
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
77-82
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:8480142-Adolescent,
pubmed-meshheading:8480142-Adult,
pubmed-meshheading:8480142-Aged,
pubmed-meshheading:8480142-Aged, 80 and over,
pubmed-meshheading:8480142-Arthritis, Rheumatoid,
pubmed-meshheading:8480142-Cohort Studies,
pubmed-meshheading:8480142-Female,
pubmed-meshheading:8480142-Gold,
pubmed-meshheading:8480142-Humans,
pubmed-meshheading:8480142-Incidence,
pubmed-meshheading:8480142-Injections,
pubmed-meshheading:8480142-Life Tables,
pubmed-meshheading:8480142-Male,
pubmed-meshheading:8480142-Middle Aged,
pubmed-meshheading:8480142-Neoplasms,
pubmed-meshheading:8480142-Patient Compliance,
pubmed-meshheading:8480142-Patient Dropouts,
pubmed-meshheading:8480142-Podophyllin,
pubmed-meshheading:8480142-Podophyllotoxin,
pubmed-meshheading:8480142-Prognosis,
pubmed-meshheading:8480142-Risk Factors,
pubmed-meshheading:8480142-Treatment Outcome
|
| pubmed:year |
1993
|
| pubmed:articleTitle |
Proresid therapy in rheumatoid arthritis. A comparison with injectable gold using life-table analysis.
|
| pubmed:affiliation |
Department of Rheumatology, Sahlgren University Hospital, Göteborg, Sweden.
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|